Clinical Trial Update: Iloprost for Prevention of Contrast-Mediated Nephropathy in High-Risk Patients Undergoing Coronary Angiography and/or Intervention [Phase 2, Phase 3]

View source ↗

Summary

Iloprost was evaluated for prevention of contrast-induced nephropathy in high-risk patients undergoing coronary angiography or PCI. The clinical trials have com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Contrast-induced Nephropathy

Drugs mentioned

• Iloprost (iloprost)

Snippet

Sponsor: Onassis Cardiac Surgery Centre | Conditions: Renal Insufficiency, Chronic, Coronary Angiography | Phase 2, Phase 3 | Status: COMPLETED